Jenan Dailey, PharmD, BCAP, spoke about the approval of lazertinib plus amivantamab as first-line treatment for patients with locally advanced or metastatic NSCLC.
Jenan Dailey, PharmD, BCAP
Advertisement
Articles by Jenan Dailey, PharmD, BCAP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
3
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
4
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
5
